These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study. Arrieta O; Caballé-Pérez E; Hernández-Pedro N; Romero-Nuñez E; Lucio-Lozada J; Castillo-Ruiz C; Acevedo-Castillo K; María Álvarez-Gómez R; Molina-Garay C; Jiménez-Olivares M; Carrillo-Sánchez K; Cristina Mendoza-Caamal E; Cardona AF; Remon J; Alaez-Verson C Lung Cancer; 2024 Jun; 194():107864. PubMed ID: 38945003 [TBL] [Abstract][Full Text] [Related]
6. Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients. Satake T; Kondo S; Tanabe N; Mizuno T; Katsuya Y; Sato J; Koyama T; Yoshida T; Hirata M; Yamamoto N Cancer Res Commun; 2023 Nov; 3(11):2302-2311. PubMed ID: 37916805 [TBL] [Abstract][Full Text] [Related]
7. Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study. Abdel-Razeq H; Al-Azzam K; Elemian S; Abu-Fares H; Abu Sheikha A; Bani Hani H; Bater R; Sharaf B; Heald B; Esplin ED; Nielsen SM; Alkyam M; Abujamous L; Al-Attary A Mol Genet Genomic Med; 2023 Apr; 11(4):e2125. PubMed ID: 36537080 [TBL] [Abstract][Full Text] [Related]
8. Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study. Nacer DF; Vallon-Christersson J; Nordborg N; Ehrencrona H; Kvist A; Borg Å; Staaf J Genome Med; 2023 Apr; 15(1):25. PubMed ID: 37060015 [TBL] [Abstract][Full Text] [Related]
10. Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. Woodward ER; van Veen EM; Forde C; Harkness EF; Byers HJ; Ellingford JM; Burghel GJ; Schlech H; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ; Gareth Evans D Genet Med; 2021 Oct; 23(10):1969-1976. PubMed ID: 34113003 [TBL] [Abstract][Full Text] [Related]
11. Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer. Rebhan K; Stelzer PD; Pradere B; Rajwa P; Kramer G; Hofmann B; Resch I; Yurdakul O; Laccone FA; Bujalkova MG; Smogavec M; Tan YY; Ristl R; Shariat SF; Egger G; Hassler MR World J Urol; 2023 Aug; 41(8):2091-2097. PubMed ID: 37528288 [TBL] [Abstract][Full Text] [Related]
12. Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers. Hao S; Zhao X; Fan Y; Liu Z; Zhang X; Li W; Yuan H; Zhang J; Zhang Y; Ma T; Tao H Cancer Med; 2023 Sep; 12(17):18394-18404. PubMed ID: 37610374 [TBL] [Abstract][Full Text] [Related]
13. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. Berchuck JE; Boiarsky D; Silver R; Sunkara R; McClure HM; Tsai HK; Siegmund S; Tewari AK; Nowak JA; Lindeman NI; Rana HQ; Choudhury AD; Pomerantz MM; Freedman ML; Van Allen EM; Taplin ME JCO Precis Oncol; 2022 Aug; 6():e2200329. PubMed ID: 36103646 [TBL] [Abstract][Full Text] [Related]
14. Disparate Rates of Germline Variants in Cancer Predisposition Genes in African American/Black Compared With Non-Hispanic White Individuals Between 2015 and 2022. Wyatt Castillo RB; Nielsen SM; Chen E; Heald B; Ellsworth RE; Esplin ED; Tomlinson GE JCO Precis Oncol; 2024 Jul; 8():e2300715. PubMed ID: 38991178 [TBL] [Abstract][Full Text] [Related]
16. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Brand R; Borazanci E; Speare V; Dudley B; Karloski E; Peters MLB; Stobie L; Bahary N; Zeh H; Zureikat A; Hogg M; Lee K; Tsung A; Rhee J; Ohr J; Sun W; Lee J; Moser AJ; DeLeonardis K; Krejdovsky J; Dalton E; LaDuca H; Dolinsky J; Colvin A; Lim C; Black MH; Tung N Cancer; 2018 Sep; 124(17):3520-3527. PubMed ID: 30067863 [TBL] [Abstract][Full Text] [Related]
17. High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands. Yoshida R; Kaneyasu T; Ueki A; Yamauchi H; Ohsumi S; Ohno S; Aoki D; Baba S; Kawano J; Matsumoto N; Nagasaki M; Ueno T; Inari H; Kobayashi Y; Takei J; Gotoh O; Nishi M; Okamura M; Kaneko K; Okawa M; Suzuki M; Amino S; Inuzuka M; Noda T; Mori S; Nakamura S Breast Cancer; 2024 Jul; ():. PubMed ID: 39003386 [TBL] [Abstract][Full Text] [Related]
18. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. Uson PLS; Samadder NJ; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Faigel DO; Fukami N; Pannala R; Kunze K; Golafshar M; Klint M; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T Clin Transl Gastroenterol; 2021 Oct; 12(10):e00414. PubMed ID: 34620795 [TBL] [Abstract][Full Text] [Related]
19. Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer. Kumari N; Singh RK; Mishra SK; L R; Mohindra S; Krishnani N Pathol Res Pract; 2021 Jan; 217():153309. PubMed ID: 33341547 [TBL] [Abstract][Full Text] [Related]
20. Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Singhal D; Hahn CN; Feurstein S; Wee LYA; Moma L; Kutyna MM; Chhetri R; Eshraghi L; Schreiber AW; Feng J; Wang PP; Babic M; Parker WT; Gao S; Moore S; Das S; Thomas D; Pattnaik S; Brown AL; D'Andrea RJ; Poplawski NK; Thomas D; Scott HS; Godley LA; Hiwase DK Leukemia; 2021 Nov; 35(11):3245-3256. PubMed ID: 33850299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]